中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 39 Issue 7
Jul.  2023
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2023  >  39(7): 1529-1534

Comparison of endoscopic therapy and TIPS in prophylaxis and treatment of variceal bleeding in decompensated portal hypertension

DOI: 10.3969/j.issn.1001-5256.2023.07.003
  • 1.

    Department of Gastroenterology, The Frist Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China

  • 2.

    Xi'an Jiaotong University Health Science Center, Xi'an 710061, China

Research funding:

Key Research and Development Program of Shaanxi Provincial in China (2020SF-073);

Key Research and Development Program of Shaanxi Provincial in China (2021SF-126);

Key Research and Development Program of Shaanxi Provincial in China (2018SF-051);

Key Research and Development Program of Shaanxi Provincial in China (2019SF-195)

More Information
  • Corresponding author: XUE Hui, zj2@mail.xjtu.edu.cn (ORICD: 0000-0003-3837-5361)
  • Received Date: 2023-05-09
  • Accepted Date: 2023-06-10
  • Published Date: 2023-07-20
    Abstract
  • Esophagogastric variceal bleeding (EGVB) is one of the main complications of decompensated portal hypertension, especially in patients with liver cirrhosis, and it often has a high mortality rate. Medication combined with endoscopy is the main prevention and treatment method for EGVB, while transjugular intrahepatic portosystemic shunt (TIPS) combined with variceal embolization can also be selected for some high-risk patients, and individualized diagnosis and treatment of portal hypertension based on hepatic venous pressure gradient should become the latest consensus and the main strategy. This article mainly reviews endoscopic therapy and TIPS for the prevention and treatment of EGVB patients with decompensated portal hypertension in terms of selection of indications, incidence rate of complications, and respective advantages and disadvantages.

     

    • FullText(HTML)
  • loading
    • References(34)
  • [1]
    de FRANCHIS R, Baveno V Faculty. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension[J]. J Hepatol, 2010, 53(4): 762-768. DOI: 10.1016/j.jhep.2010.06.004.
    [2]
    GARCIA-TSAO G, ABRALDES JG, BERZIGOTTI A, et al. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases[J]. Hepatology, 2017, 65(1): 310-335. DOI: 10.1002/hep.28906.
    [3]
    de FRANCHIS R, Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension[J]. J Hepatol, 2015, 63(3): 743-752. DOI: 10.1016/j.jhep.2015.05.022.
    [4]
    BOSCH J, GARCÍA-PAGÁN JC. Prevention of variceal rebleeding[J]. Lancet, 2003, 361(9361): 952-954. DOI: 10.1016/S0140-6736(03)12778-X.
    [5]
    MOITINHO E, ESCORSELL A, BANDI JC, et al. Prognostic value of early measurements of portal pressure in acute variceal bleeding[J]. Gastroenterology, 1999, 117(3): 626-631. DOI: 10.1016/s0016-5085(99)70455-5.
    [6]
    KOVALAK M, LAKE J, MATTEK N, et al. Endoscopic screening for varices in cirrhotic patients: data from a national endoscopic database[J]. Gastrointest Endosc, 2007, 65(1): 82-88. DOI: 10.1016/j.gie.2006.08.023.
    [7]
    MERLI M, NICOLINI G, ANGELONI S, et al. Incidence and natural history of small esophageal varices in cirrhotic patients[J]. J Hepatol, 2003, 38(3): 266-272. DOI: 10.1016/s0168-8278(02)00420-8.
    [8]
    AMITRANO L, GUARDASCIONE MA, MANGUSO F, et al. The effectiveness of current acute variceal bleed treatments in unselected cirrhotic patients: refining short-term prognosis and risk factors[J]. Am J Gastroenterol, 2012, 107(12): 1872-1878. DOI: 10.1038/ajg.2012.313.
    [9]
    YOSHIJI H, NAGOSHI S, AKAHANE T, et al. Evidence-based clinical practice guidelines for liver cirrhosis 2020[J]. Hepatol Res, 2021, 51(7): 725-749. DOI: 10.1111/hepr.13678.
    [10]
    de FRANCHIS R, BOSCH J, GARCIA-TSAO G, et al. Baveno VⅡ - Renewing consensus in portal hypertension[J]. J Hepatol, 2022, 76(4): 959-974. DOI: 10.1016/j.jhep.2021.12.022.
    [11]
    DONG H, CHEN W, CHEN H, et al. New progress in endoscopic hemostasis treatment of esophageal and gastric variceal bleeding with portal hypertension in liver cirrhosis[J]. China Prac Med, 2011, 6(19): 82-83. DOI: 10.3969/j.issn.1673-7555.2011.19.053.

    董辉, 陈武, 陈贺, 等. 肝硬化门脉高压食管胃底静脉曲张出血内镜下止血治疗新进展[J]. 中国实用医药, 2011, 6(19): 82-83. DOI: 10.3969/j.issn.1673-7555.2011.19.053.
    [12]
    TANG YY, LE MX, LIU DL. Optimited application of sclerosing against in the prevention and treatment of esophageal variceal bleeding in cirrhosis[J/CD]. Chin J Gastrointestial Endoscopy (Electronic Editon), 2020, 7(1): 39-42. DOI: 10.3877/cma.j.issn.2095-7157.2020.01.010.

    谭玉勇, 乐梅先, 刘德良. 硬化剂在肝硬化食管静脉曲张破裂出血防治中的优化应用[J/CD]. 中华胃肠内镜电子杂志, 2020, 7(1): 39-42. DOI: 10.3877/cma.j.issn.2095-7157.2020.01.010.
    [13]
    LI X, JIANG T, GAO J. Endoscopic variceal ligation combined with argon plasma coagulation versus ligation alone for the secondary prophylaxis of variceal bleeding: a systematic review and meta-analysis[J]. Eur J Gastroenterol Hepatol, 2017, 29(6): 621-628. DOI: 10.1097/MEG.0000000000000861.
    [14]
    HENRY Z, PATEL K, PATTON H, et al. AGA clinical practice update on management of bleeding gastric varices: expert review[J]. Clin Gastroenterol Hepatol, 2021, 19(6): 1098-1107. e1. DOI: 10.1016/j.cgh.2021.01.027.
    [15]
    GREENWALD BD, CALDWELL SH, HESPENHEIDE EE, et al. N-2-butyl-cyanoacrylate for bleeding gastric varices: a United States pilot study and cost analysis[J]. Am J Gastroenterol, 2003, 98(9): 1982-1988. DOI: 10.1111/j.1572-0241.2003.07637.x.
    [16]
    GUO YW, MIAO HB, WEN ZF, et al. Procedure-related complications in gastric variceal obturation with tissue glue[J]. World J Gastroenterol, 2017, 23(43): 7746-7755. DOI: 10.3748/wjg.v23.i43.7746.
    [17]
    WANG FH, LONG D, ZHU JC, et al. Clinical observation on the treatment of gastric varices with modified sandwich sandwich tissue gel injection under endoscopy[J]. J Med Theor & Pract, 2019, 32(19): 3099-3100. DOI: 10.19381/j.issn.1001-7585.2019.19.028.

    王富华, 龙丹, 朱建臣, 等. 内镜下改良三明治夹心法组织胶注射治疗胃静脉曲张的临床观察[J]. 医学理论与实践, 2019, 32(19): 3099-3100. DOI: 10.19381/j.issn.1001-7585.2019.19.028.
    [18]
    ROMERO-CASTRO R, ELLRICHMANN M, ORTIZ-MOYANO C, et al. EUS-guided coil versus cyanoacrylate therapy for the treatment of gastric varices: a multicenter study (with videos)[J]. Gastrointest Endosc, 2013, 78(5): 711-721. DOI: 10.1016/j.gie.2013.05.009.
    [19]
    MONESCILLO A, MARTÍNEZ-LAGARES F, RUIZ-DEL-ARBOL L, et al. Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding[J]. Hepatology, 2004, 40(4): 793-801. DOI: 10.1002/hep.20386.
    [20]
    GARCÍA-PAGÁN JC, CACA K, BUREAU C, et al. Early use of TIPS in patients with cirrhosis and variceal bleeding[J]. N Engl J Med, 2010, 362(25): 2370-2379. DOI: 10.1056/NEJMoa0910102.
    [21]
    HERNÁNDEZ-GEA V, PROCOPET B, GIRÁLDEZ Á, et al. Preemptive-TIPS improves outcome in high-risk variceal bleeding: an observational study[J]. Hepatology, 2019, 69(1): 282-293. DOI: 10.1002/hep.30182.
    [22]
    NICOARǍ-FARCǍU O, HAN G, RUDLER M, et al. Effects of early placement of transjugular portosystemic shunts in patients with high-risk acute variceal bleeding: a meta-analysis of individual patient data[J]. Gastroenterology, 2021, 160(1): 193-205. e10. DOI: 10.1053/j.gastro.2020.09.026.
    [23]
    HALABI SA, SAWAS T, SADAT B, et al. Early TIPS versus endoscopic therapy for secondary prophylaxis after management of acute esophageal variceal bleeding in cirrhotic patients: a meta-analysis of randomized controlled trials[J]. J Gastroenterol Hepatol, 2016, 31(9): 1519-1526. DOI: 10.1111/jgh.13303.
    [24]
    NJEI B, MCCARTY TR, LAINE L. Early transjugular intrahepatic portosystemic shunt in US patients hospitalized with acute esophageal variceal bleeding[J]. J Gastroenterol Hepatol, 2017, 32(4): 852-858. DOI: 10.1111/jgh.13593.
    [25]
    BUREAU C, THABUT D, OBERTI F, et al. Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites[J]. Gastroenterology, 2017, 152(1): 157-163. DOI: 10.1053/j.gastro.2016.09.016.
    [26]
    ZHANG M, WANG G, ZHAO L, et al. Second prophylaxis of variceal bleeding in cirrhotic patients with a high HVPG[J]. Scand J Gastroenterol, 2016, 51(12): 1502-1506. DOI: 10.1080/00365521.2016.1193218.
    [27]
    LV Y, QI X, HE C, et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial[J]. Gut, 2018, 67(12): 2156-2168. DOI: 10.1136/gutjnl-2017-314634.
    [28]
    TRIPATHI D, THERAPONDOS G, JACKSON E, et al. The role of the transjugular intrahepatic portosystemic stent shunt (TIPSS) in the management of bleeding gastric varices: clinical and haemodynamic correlations[J]. Gut, 2002, 51(2): 270-274. DOI: 10.1136/gut.51.2.270.
    [29]
    SAAD WE, WAGNER CC, LIPPERT A, et al. Protective value of TIPS against the development of hydrothorax/ascites and upper gastrointestinal bleeding after balloon-occluded retrograde transvenous obliteration (BRTO)[J]. Am J Gastroenterol, 2013, 108(10): 1612-1619. DOI: 10.1038/ajg.2013.232.
    [30]
    Minimally Invasive Intervention Group, Chinese Society of Gastroenterology. Expert consensus on transjugular intrahepatic portosystemic shunt for the treatment of portal hypertension[J]. Chin J Hepatol, 2022, 30(12): 1349-1364. DOI: 10.3760/cma.j.cn501113-20221109-00553.

    中华医学会消化病学分会微创介入协作组. 经颈静脉肝内门体静脉分流术治疗门静脉高压专家共识(2022年版)[J]. 中华肝脏病杂志, 2022, 30(12): 1349-1364. DOI: 10.3760/cma.j.cn501113-20221109-00553.
    [31]
    LI PJ, XU J, YAN LJ, et al. Comparison of five-year survival status of patients with liver cirrhosis and esophagogastric varices bleeding treated by transjugular intrahepatic portosystemic shunt and drug combined with endoscopic treatment[J]. Chin J Dig, 2021, 41(5): 323-329. DOI: 10.3760/cma.j.cn311367-20200828-00518.

    李培杰, 徐菁, 闫丽晶, 等. 经颈静脉肝内门体分流术与药物联合内镜治疗肝硬化食管胃静脉曲张出血患者五年生存状况比较[J]. 中华消化杂志, 2021, 41(5): 323-329. DOI: 10.3760/cma.j.cn311367-20200828-00518.
    [32]
    WANG CY, XIONG B, LIU JC, et al. Effect of underdilated stent on the occurrence of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt creation[J]. Chin J Intern Med, 2022, 61(5): 537-542. DOI: 10.3760/cma.j.cn112138-20211010-00685.

    王朝阳, 熊斌, 刘家成, 等. 支架亚扩张对经颈静脉肝内门体分流术后肝性脑病发生率的影响分析[J]. 中华内科杂志, 2022, 61(5): 537-542. DOI: 10.3760/cma.j.cn112138-20211010-00685.
    [33]
    YANG MZ, WU D, TANG L, et al. Clinical features of hepatic myelopathy: An analysis of 562 cases[J]. J Clin Hepatol, 2021, 37(1): 115-119. DOI: 10.3969/j.issn.1001-5256.2021.01.023.

    杨明芝, 吴丹, 唐亮, 等. 562例肝性脊髓病的临床特征分析[J]. 临床肝胆病杂志, 2021, 37(1): 115-119. DOI: 10.3969/j.issn.1001-5256.2021.01.023.
    [34]
    MA FQ, HUANG J, LI WZ, et al. Effects of reduced portosystemic flow on hepatic myelopathy in patients with cirrhosis after TIPS[J]. Chin J Hepatol, 2022, 30(10): 1063-1068. DOI: 10.3760/cma.j.cn501113-20201026-00580.

    马富权, 黄金, 李伟之, 等. 减少门腔分流量对肝硬化患者经颈静脉肝内门体分流术后肝性脊髓病的影响[J]. 中华肝脏病杂志, 2022, 30(10): 1063-1068. DOI: 10.3760/cma.j.cn501113-20201026-00580.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (632) PDF downloads(126) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return